Type 1 diabetes market value to double by 2023
pharmafile | March 19, 2015 | News story | Research and Development, Sales and Marketing | GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts at GlobalData.
Increasing cases of diabetes combined with higher costs of therapy are likely to be factors in the market expanding from $6.6 billion in 2013, says the research and consulting firm.
GlobalData’s report calculates that this increase represents a compound annual growth rate (CAGR) of 7.6 per cent.
Dr Valentina Gburcik, who is the company’s therapy director of cardiovascular and metabolic disorders, says: “The US will remain the leading market largely thanks to its average insulin price, which is about five to six times greater than in the other major markets.
“Furthermore, the uptake of novel ultra-long-acting insulin analogues, novel ultra-rapid formulations of insulin analogues, and adjunct therapies for type 1 in the US market will help to offset the dip in sales caused by the patent expiries of seven insulin products by 2023.”
The report also predicts that human insulins and analogues will remain front-line therapies for the condition, as none of the treatments on the horizon over the next 10 years will have the capacity to enable full regeneration of pancreatic beta cells.
One such insulin product hitting the headlines recently was Sanofi’s Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) when it was approved last month by US regulators.
The once-daily long-acting basal insulin to improve glycemic control in adults living with type 1 and type 2 diabetes, is expected to be available in the US later this year.
Additionally, NICE guidance on both types of diabetes in adults and children changed in late 2014 following ‘major advances’ in the management of the condition.
The Health Survey for England found that there are over 370,000 adults with type 1 diabetes in the UK today. The recommendations suggest multiple daily injection basal bolus insulin, rather than twice-daily mixed insulin regimens, as first-choice insulin injections.
According to Diabetes UK, type 1 accounts for about 10% of all adults with diabetes. It can develop at any age but usually appears before the age of 40, and especially in childhood.
Tom Robinson
Related Content
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
